ERBB2 and breast cancer: Monoclonal antibodies targeting overexpressed receptors such as human epidermal growth factor receptor 2 (HER2) in breast cancer [36], epidermal growth factor receptor (EGFR) in lung and oral cancers [37, 38] and CD20 in lymphomas [39] have been successfully conjugated to both chemically synthesized and eco-AgNPs, demonstrating enhanced therapeutic efficacy and reduced systemic toxicity [2].